Drug intelligence / Profile preview

nuvisertib

Development stage: Phase 2
Lead developer: Sumitomo Pharma America
Modality: Small Molecules
Administration: Oral

Overview

Nuvisertib is an oral investigational small molecule drug that acts as a selective inhibitor of PIM1 kinase, with potential antitumor and antifibrotic activities. It is being developed for the treatment of myelofibrosis and has shown promise in preclinical models by inducing apoptosis and inhibiting proliferation in hematopoietic cells. Nuvisertib is also being evaluated in combination with other drugs like ruxolitinib and momelotinib.

Other names: SGI 9481SGI9481SGI-9481

Targets

PIM1 (Proviral integration site for moloney murine leukemia virus kinase 1)PIM2 (Proto-oncogene serine/threonine-protein kinase Pim2)PIM3 (Proviral integration site for Moloney murine leukemia virus kinase 3)

Beyond the preview

Go deeper on nuvisertib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nuvisertib.

Explore the full profile